Moneycontrol PRO
you are here: HomeNewsNatco pharma
natco pharma
Jump to
458 Results Found
  • Natco Pharma share price falls 5% on setback in US patent litigation Aug 20, 2021 01:10 PM IST

    Natco Pharma share price falls 5% on setback in US patent litigation

    Natco and partner Alvogen are reviewing the order and will evaluate all options to appeal the judgment, the pharma firm has said

  • Natco Pharma Standalone June 2021 Net Sales at Rs 393.80 crore, down 26.01% Y-o-Y Aug 13, 2021 09:33 AM IST

    Natco Pharma Standalone June 2021 Net Sales at Rs 393.80 crore, down 26.01% Y-o-Y

  • Natco Pharma Q1 net profit declines 39% to Rs 75 crore Aug 12, 2021 04:40 PM IST

    Natco Pharma Q1 net profit declines 39% to Rs 75 crore

    The company had posted a net profit of Rs 122.1 crore for the corresponding period of the previous fiscal, Natco Pharma said in regulatory filing.

  • Hold Natco Pharma; target of Rs 1010: ICICI Direct Jun 21, 2021 04:24 PM IST

    Hold Natco Pharma; target of Rs 1010: ICICI Direct

    ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 1010 in its research report dated June 18, 2021.

  • Natco Pharma net dips 43% to Rs 53 crore in Q4 Jun 17, 2021 10:00 PM IST

    Natco Pharma net dips 43% to Rs 53 crore in Q4

    Total income during the fourth quarter stood at Rs 360 crore, down from Rs 477 crore in the fourth quarter of the financial year 2019-20, the drugmaker said in a regulatory filing.

  • Natco Pharma Standalone March 2021 Net Sales at Rs 311.50 crore, down 25.85% Y-o-Y Jun 17, 2021 08:33 PM IST

    Natco Pharma Standalone March 2021 Net Sales at Rs 311.50 crore, down 25.85% Y-o-Y

  • Natco Pharma Consolidated March 2021 Net Sales at Rs 331.30 crore, down 27.15% Y-o-Y Jun 17, 2021 08:33 PM IST

    Natco Pharma Consolidated March 2021 Net Sales at Rs 331.30 crore, down 27.15% Y-o-Y

  • Natco Pharma's marketing partner gets USFDA nod for anti-cancer drug Jun 14, 2021 12:18 PM IST

    Natco Pharma's marketing partner gets USFDA nod for anti-cancer drug

    "Breckenridge Pharmaceutical Inc. (BPI), has received approval for its abbreviated new drug application (ANDA) for Carfilzomib Vials ANDA (generic for Kyprolis), from the US Food and Drug Administration (USFDA)," Natco Pharma said in a regulatory filing.

  • Natco Pharma share price hits 52- week high on DCGI nod for production of 'Black Fungus' drug May 24, 2021 09:58 AM IST

    Natco Pharma share price hits 52- week high on DCGI nod for production of 'Black Fungus' drug

    DCGI approved application of five companies incuding Natco Pharma to begin production of antifungal drug Amphotericin B liposomal injection, which is critical in the treatment of Mucormycosis, also called 'Black Fungus'.

  • How Natco Pharma put US drug giant Eli Lilly under pressure for COVID-19 drug through compulsory licensing filing May 05, 2021 04:27 PM IST

    How Natco Pharma put US drug giant Eli Lilly under pressure for COVID-19 drug through compulsory licensing filing

    The Indian company says it has offered 7% royalty to the US drugmaker for Baricitinib. Natco has filed for compulsory licensing, arguing that Eli Lilly’s small distribution network won’t be able to serve India’s population and the 14-day, Rs 42,000 per-patient treatment regimen for the US drug is too expensive.

  • Eli Lilly India chief says company in talks with generic firms here on royalty free voluntary licensing of COVID-19 drug Baricitinib May 05, 2021 02:45 PM IST

    Eli Lilly India chief says company in talks with generic firms here on royalty free voluntary licensing of COVID-19 drug Baricitinib

    They are also working with regulatory authorities and the government of India to donate Lilly’s COVID-19 treatments, including Baricitinib, if authorities deem it appropriate to potentially provide relief

  • Natco Pharma share price up over 4% on emergency approval for COVID-19 medicine May 03, 2021 09:44 AM IST

    Natco Pharma share price up over 4% on emergency approval for COVID-19 medicine

    Baricitinib in combination with Remdesivir is used for the treatment of COVID-19 positive patients.

  • Natco Pharma seeks approval for COVID drug candidate Molnupiravir; shares jump 7% Apr 26, 2021 11:00 AM IST

    Natco Pharma seeks approval for COVID drug candidate Molnupiravir; shares jump 7%

    Natco said it is hoping that CDSCO would give emergency approval of this drug based on “compassionate use” for patients.

  • Natco Pharma share price rises nearly 8% after marketing partner gets final US FDA approval Mar 08, 2021 10:53 AM IST

    Natco Pharma share price rises nearly 8% after marketing partner gets final US FDA approval

    The share touched a 52-week high of Rs 996 and a 52-week low of Rs 402.55 on 07 December 2020 and 25 March 2020, respectively.

  • Natco Pharma launches epilepsy treatment drug Brivaracetam in India Feb 26, 2021 01:28 PM IST

    Natco Pharma launches epilepsy treatment drug Brivaracetam in India

    Brivaracetam, indicated towards treatment of epilepsy, is developed by UCB Pharma and currently marketed in India by Dr Reddy's under brand name Briviact.

  • Natco Pharma Consolidated December 2020 Net Sales at Rs 355.20 crore, down 26.34% Y-o-Y Feb 11, 2021 06:00 PM IST

    Natco Pharma Consolidated December 2020 Net Sales at Rs 355.20 crore, down 26.34% Y-o-Y

  • Natco Pharma Standalone December 2020 Net Sales at Rs 330.90 crore, down 26.09% Y-o-Y Feb 11, 2021 06:00 PM IST

    Natco Pharma Standalone December 2020 Net Sales at Rs 330.90 crore, down 26.09% Y-o-Y

  • Natco Pharma gets registration approval from CIB&RC for Chlorantraniliprole Feb 05, 2021 12:24 PM IST

    Natco Pharma gets registration approval from CIB&RC for Chlorantraniliprole

    Natco would be the first indigenous manufacturer of this technical product, the company added.

  • Hold Natco Pharma; target of Rs 970: ICICI Direct Nov 17, 2020 12:47 PM IST

    Hold Natco Pharma; target of Rs 970: ICICI Direct

    ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 970 in its research report dated November 13, 2020.

  • Natco Pharma Q2 net profit up 73% to Rs 204 crore Nov 12, 2020 05:34 PM IST

    Natco Pharma Q2 net profit up 73% to Rs 204 crore

    The company had posted a net profit of Rs 117.7 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing.

  • Natco Pharma aims to diversify product portfolio in domestic market Sep 21, 2020 03:35 PM IST

    Natco Pharma aims to diversify product portfolio in domestic market

    New Delhi, Sep 21 Natco Pharma plans to diversify its product portfolio in the domestic market as it aims to make up for a drop in business of some..

  • Buy Natco Pharma: target of Rs 954: ICICI Securities Sep 18, 2020 04:51 PM IST

    Buy Natco Pharma: target of Rs 954: ICICI Securities

    ICICI Securities is bullish on Natco Pharma recommended buy rating on the stock with a target price of Rs 954 in its research report dated September 18, 2020.

  • Hold Natco Pharma; target of Rs 881: Geojit Aug 16, 2020 09:10 AM IST

    Hold Natco Pharma; target of Rs 881: Geojit

    Geojit recommended accumulate rating on Natco Pharma with a target price of Rs 881 in its research report dated August 14, 2020.

  • Buy Natco Pharma; target of Rs 950: ICICI Direct Aug 14, 2020 12:22 PM IST

    Buy Natco Pharma; target of Rs 950: ICICI Direct

    ICICI Direct is bullish on Natco Pharma has recommended buy rating on the stock with a target price of Rs 950 in its research report dated August 13, 2020.

  • Natco Pharma Q1 net profit declines 14.5% to Rs 122 crore Aug 12, 2020 04:35 PM IST

    Natco Pharma Q1 net profit declines 14.5% to Rs 122 crore

    The company had posted a net profit of Rs 142.8 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing.

Sections
ISO 27001 - BSI Assurance Mark